Research analysts at HC Wainwright assumed coverage on shares of TrovaGene (NASDAQ:TROV) in a research report issued on Thursday, MarketBeat reports. The firm set a “buy” rating and a $1.00 price target on the medical research company’s stock. HC Wainwright’s target price would indicate a potential upside of 300.00% from the stock’s current price.
Other analysts have also recently issued research reports about the stock. Maxim Group set a $4.00 price objective on shares of TrovaGene and gave the stock a “buy” rating in a report on Wednesday, October 18th. cut shares of TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $3.70.
TrovaGene (NASDAQ TROV) remained flat at $$0.25 during trading on Thursday. The stock had a trading volume of 1,361,700 shares, compared to its average volume of 630,276. TrovaGene has a twelve month low of $0.24 and a twelve month high of $2.85.
Several hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP increased its holdings in shares of TrovaGene by 254.2% in the 3rd quarter. Susquehanna International Group LLP now owns 488,937 shares of the medical research company’s stock worth $357,000 after acquiring an additional 350,906 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of TrovaGene by 1,079.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock worth $351,000 after acquiring an additional 254,601 shares during the period. Finally, LMR Partners LLP acquired a new stake in shares of TrovaGene in the 2nd quarter worth about $151,000. 13.73% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “TrovaGene (TROV) Earns Buy Rating from Analysts at HC Wainwright” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/12/21/trovagene-trov-earns-buy-rating-from-analysts-at-hc-wainwright.html.
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.